surmount-1 tirzepatide non-diabetic obesity weight loss reduction with different doses of in Surmount 1 SURMOUNT-1 Trial Summary: What Tirzepatide

Its injected once weekly and is expected to be submitted to the FDA for approval in 2026

In dit blok beantwoorden we veelgestelde vragen over veiligheid, verwachtingen en het verloop van de behandeling

Individual safety findings for one molecule dont necessarily predict class-wide effects, says Finer, safety signals often relate to specific structural features or off-target activities rather than the primary mechanism of action. He thinks oral GLP-1 drugs have the potential for better dose titration, which might help control the current, mainly gastrointestinal, side-effects of the injectable peptides

Raza A, et al

Itching is not listed as a frequent side effect of semaglutide in major clinical trial data